Anticarcinogenic role of melatonin-potential mechanisms;Rola melatoniny w procesach antynowotworowych-potencjalne mechanizmy

Medycyna Pracy

Volumn 62, Issue 4, 2011, Pages 425-434

  Bukowska, Agnieszka ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Hormone dependent tumors; Melatonin; Oxidative stress

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; MELATONIN; PROTECTIVE AGENT;

ANIMAL; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; NEOPLASM; OXIDATION REDUCTION REACTION; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; EVIDENCE-BASED MEDICINE; HUMANS; MELATONIN; NEOPLASMS, HORMONE-DEPENDENT; OXIDATION-REDUCTION; PROTECTIVE AGENTS; RESEARCH DESIGN;

EID: 80052908118     PISSN: 04655893     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Cohen M., Lippman M., Chabner B.: Pineal gland and breast cancer. Lancet 1978;2(8104):1381-1382
2. Stevens R.G.: Electric power use and breast cancer: a hypothesis. Am. J. Epidemiol. 1987;125(4):556-561
3. Marie H.A., Helene G.A., Hansen J.: Diurnal urinary 6-sulfatoxymelatonin levels among healthy Danish nurses during work and leisure time. Chronobiol. Int. 2006;23(6):1203-1215
4. Schernhammer E.S., Berrino F., Krogh V., Secreto G., Micheli A., Venturelli E. i wsp.: Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol. Biomarkers Prev. 2010;19(3):729-737
5. Travis R.C., Allen D.S., Fentiman I.S., Key T.J.: Melatonin and breast cancer: a prospective study. J. Natl. Cancer Inst. 2004;96(6):475-482
6. Brudnowska J., Pepłońska B.: Praca zmianowa nocna a ryzyko choroby nowotworowej - przegla̧d literatury. Med. Pr. 2011;62(3):323-338
7. Arendt J., Skene D.J.: Melatonin as a chronobiotic. Sleep Med. Rev. 2005;9(1):25-39
8. Gastel J.A., Roseboom P.H., Rinaldi P.A., Weller J.L., Klein D.C.: Melatonin production: proteasomal proteolysis in serotonin N-acetyltransferase regulation. Science 1998;279(5355):1358-1360
9. Ekmekcioglu C.: Melatonin receptors in humans: biological role and clinical relevance. Biomed. Pharmacother. 2006;60(3):97-108
10. Huan C., Zhou M., Wu M., Zhang Z., Mei Y.: Activation of melatonin receptor increases a delayed rectifier K+ current in rat cerebellar granule cells. Brain Res. 2001;917(2):182-190
11. Godson C., Reppert S.M.: The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology 1997;138(1):397-404
12. Picinato M.C, Haber E.P., Cipolla-Neto J., Curi R., de Oliveira Carvalho C.R., Carpinelli A.R.: Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J. Pineal. Res. 2002;33(3):156-160
13. Pandi-Perumal S.R., Srinivasan V., Maestroni G.J., Cardinali D.P., Poeggeler B., Hardeland R:. Melatonin: Nature's most versatile biological signal? FEBS J. 2006;273(13):2813-2838
14. Skene D.J., Arendt J.: Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med. 2007;8(6):651-655
15. Aleandri V., Spina V., Morini A.: The pineal gland and reproduction. Hum. Reprod. Update 1996;2(3):225-235
16. Roy D., Belsham D.D.: Melatonin receptor activation regulates GnRH gene expression and secretion in GT1-7 GnRH neurons. Signal transduction mechanisms. J. Biol. Chem. 2002;277(1):251-258
17. Soares J.M. Jr, Masana M.I., Ersahin C., Dubocovich M.L.: Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J. Pharmacol. Exp. Ther. 2003;306(2):694-702
18. Sanchez J.J., Abreu P., Gonzalez-Hernandez T., Hernandez A., Prieto L., Alonso R.: Estrogen modulation of adrenoceptor responsiveness in the female rat pineal gland: differential expression of intracellular estrogen receptors. J. Pineal. Res. 2004;37(1):26-35
19. Berga S.L., Mortola J.F., Yen S.S.: Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 1988;66(1):242-244
20. Lenoir V., de Jonage-Canonico M.B., Perrin M.H., Martin A., Scholler R., Kerdelhue B.: Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague- -Dawley rat. Breast Cancer Res. 2005;7(4):R470-R476
21. Cos S., Sanchez-Barcelo E.J.: Melatonin and mammary pathological growth. Front. Neuroendocrinol. 2000;21(2):133-170
22. Tamarkin L., Cohen M., Roselle D., Reichert C., Lippman M., Chabner B.: Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 1981;41(11 Pt 1):4432-4436
23. Shah P.N., Mhatre M.C., Kothari L.S.: Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res. 1984;44(8):3403-3407
24. Blask D.E., Pelletier D.B., Hill S.M., Lemus-Wilson A., Grosso D.S., Wilson S.T. i wsp.: Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J. Cancer Res. Clin. Oncol. 1991;117(6):526-532
25. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintreub S.T. i wsp: A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998;253(3):614-620
26. Pieri C., Moroni F., Marra M., Marcheselli F., Recchioni R.: Melatonin is an efficient antioxidant. Arch. Gerontol. Geriatr. 1995;20(2):159-165
27. Ozturk G., Coskun S., Erbas D., Hasanoglu E.: The effect of melatonin on liver superoxide dismutase activity, serum nitrate and thyroid hormone levels. Jpn. J. Physiol. 2000;50(1):149-153
28. Okatani Y., Wakatsuki A., Kaneda C.: Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J. Pineal. Res. 2000;28(2): 89-96
29. Tomas-Zapico C., Coto-Montes A., Martinez-Fraga J., Rodriguez-Colunga M.J., Hardeland R., Tolivia D.: Effects of delta-aminolevulinic acid and melatonin in the harderian gland of female Syrian hamsters. Free Radic. Biol. Med. 2002;32(11):1197-1204
30. Bettahi I., Pozo D., Osuna C., Reiter R.J., Acuna- -Castroviejo D., Guerrero J.M.: Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J. Pineal. Res. 1996;20(4):205-210
31. Gulcin I., Buyukokuroglu M.E., Kufrevioglu O.I.: Metal chelating and hydrogen peroxide scavenging effects of melatonin. J. Pineal. Res. 2003;34(4):278-281
32. Cagnoli C.M., Atabay C., Kharlamova E., Manev H.: Melatonin protects neurons from singlet oxygen-induced apoptosis. J. Pineal. Res. 1995;18(4):222-226
33. Antolin I., Rodriguez C., Sainz R.M., Mayo J.C., Uria H., Kotler M.L. i wsp.: Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J. 1996;10(8):882-890
34. Mayo J.C., Sainz R.M., Antoli I., Herrera F., Martin V., Rodriguez C.: Melatonin regulation of antioxidant enzyme gene expression. Cell. Mol. Life Sci. 2002;59(10):1706-1713
35. Esparza J.L., Gomez M., Rosa N.M., Paternain J.L., Mallol J., Domingo J.L.: Melatonin reduces oxidative stress and increases gene expression in the cerebral cortex and cerebellum of aluminum-exposed rats. J. Pineal. Res. 2005;39(2):129-136
36. Urata Y., Honma S., Goto S., Todoroki S., Iida T., Cho S. i wsp.: Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med. 1999;27(7-8): 838-847
37. Erat M., Ciftci M.: Effect of melatonin on enzyme activities of glutathione reductase from human erythrocytes in vitro and from rat erythrocytes in vivo. Eur. J. Pharmacol. 2006;537(1-3):59-63
38. Maestroni G.J., Conti A., Pierpaoli W.: Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J. Neuroimmunol. 1986;13(1):19-30
39. Del G.V., Libri V., Villani N., Calio R., Nistico G.: Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int. J. Immunopharmacol. 1989;11(5):567-573
40. Pawlak J., Singh J., Lea R.W., Skwarlo-Sonta K.: Effect of melatonin on phagocytic activity and intracellular free calcium concentration in testicular macrophages from normal and streptozotocin-induced diabetic rats. Mol. Cell. Biochem. 2005;275(1-2):207-213
41. Garcia-Maurino S., Gonzalez-Haba M.G., Calvo J.R., Rafii-El-Idrissi M., Sanchez-Margalet V., Goberna R. i wsp.: Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 1997;159(2):574-581
42. Garcia-Maurino S., Pozo D., Carrillo-Vico A., Calvo J.R., Guerrero J.M.: Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci. 1999;65(20): 2143-2150
43. Radogna F., Paternoster L., Albertini M.C., Cerella C., Accorsi A., Bucchini A. i wsp.: Melatonin antagonizes apoptosis via receptor interaction in U937 monocytic cells. J. Pineal. Res. 2007;43(2):154-162
44. Carrillo-Vico A., Calvo J.R., Abreu P., Lardone P.J., Garcia-Maurino S., Reiter R.J. i wsp.: Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/ /or paracrine substance. FASEB J. 2004;18(3):537-539
45. Yuan L., Collins A.R., Dai J., Dubocovich M.L., Hill S.M.: MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol. Cell. Endocrinol. 2002;192(1-2): 147-156
46. Cos S., Blask D.E., Lemus-Wilson A., Hill A.B.: Effects of melatonin on the cell cycle kinetics and "estrogen- -rescue" of MCF-7 human breast cancer cells in culture. J. Pineal. Res. 1991;10(1):36-42
47. Cos S., Recio J., Sanchez-Barcelo E.J.: Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci. 1996;58(9):811-816
48. Cos S., Fernandez F., Sanchez-Barcelo E.J.: Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci. 1996;58(26):2447-2453
49. Mediavilla M.D., Cos S., Sanchez-Barcelo E.J.: Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999;65(4):415-420
50. Akiyama T., Yoshida T., Tsujita T., Shimizu M., Mizukami T., Okabe M. i wsp.: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 1997;57(8):1495-1501
51. Crespo D., Fernandez-Viadero C., Verduga R., Ovejero V., Cos S.: Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J. Pineal. Res. 1994;16(4):215-222
52. Cos S., Mediavilla M.D., Fernandez R., Gonzalez- -Lamuno D., Sanchez-Barcelo E.J.: Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J. Pineal. Res. 2002;32(2):90-96
53. Hill S.M., Spriggs L.L., Simon M.A., Muraoka H., Blask D.E.: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett. 1992;64(3):249-256
54. Rato A.G., Pedrero J.G., Martinez M.A., del R.B., Lazo P.S., Ramos S.: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 1999;13(8): 857-868
55. Girgert R., Hanf V., Emons G., Grundker C.: Membrane- -bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J. Pineal. Res. 2009;47(1):23-31
56. Aronica S.M., Kraus W.L., Katzenellenbogen B.S.: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. U.S.A. 1994;91(18):8517-8521
57. Brydon L., Roka F., Petit L., de Coppet P., Tissot M., Barrett P. i wsp.: Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol. Endocrinol. 1999;13(12):2025-2038
58. Cos S., Martinez-Campa C., Mediavilla M.D., Sanchez-Barcelo E.J.: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J. Pineal. Res. 2005;38(2):136-142
59. Gonzalez A., Martinez-Campa C., Mediavilla M.D., Alonso-Gonzalez C., Sanchez-Mateos S., Hill S.M. i wsp.: Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol. Rep. 2007;17(4):947-953
60. Cos S., Gonzalez A., Guezmes A., Mediavilla M.D., Martinez-Campa C., Alonso-Gonzalez C. i wsp.: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer 2006;118(2):274-278
61. Garcia Pedrero J.M., del Rio B., Martinez-Campa C., Muramatsu M., Lazo P.S., Ramos S.: Calmodulin is a selective modulator of estrogen receptors. Mol. Endocrinol. 2002;16(5):947-960
62. Benitez-King G., Huerto-Delgadillo L., Anton-Tay F.: Binding of 3H-melatonin to calmodulin. Life Sci. 1993;53(3):201-207
63. Blask D.E., Dauchy R.T., Sauer L.A., Krause J.A.: Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 2004;25(6):951-960
64. Sauer L.A., Dauchy R.T., Blask D.E., Armstrong B.J., Scalici S.: 13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo. Cancer Res. 1999;59(18):4688-4692
65. Petranka J., Baldwin W., Biermann J., Jayadev S., Barrett J.C., Murphy E.: The oncostatic action of melatonin in an ovarian carcinoma cell line. J. Pineal. Res. 1999;26(3):129-136
66. Farriol M., Venereo Y., Orta X., Castellanos J.M., Segovia-Silvestre T.: In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J. Appl. Toxicol. 2000;20(1):21-24
67. Kanishi Y., Kobayashi Y., Noda S., Ishizuka B., Saito K.: Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J. Pineal. Res. 2000;28(4):227-233